Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified
release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and
nighttime heartburn over 4 weeks in subjects with symptomatic, nonerosive gastroesophageal
reflux disease (GERD).